(Q38343224)

2 September 2017

YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity (English)

1 reference

2 September 2017

1 reference

1 reference

8

Colleen C Nelson

1 reference

2 September 2017

6

Susan Ettinger

1 reference

2 September 2017

3

Tanis G Whitmore

1 reference

2 September 2017

Pepita Giménez-Bonafé

1

1 reference

2 September 2017

Matthew N Fedoruk

2

1 reference

2 September 2017

Majid Akbari

4

1 reference

2 September 2017

Jody L Ralph

5

1 reference

2 September 2017

Martin E Gleave

7

1 reference

2 September 2017

1 May 2004

1 reference

2 September 2017

1 reference

2 September 2017

59

1 reference

2 September 2017

337-349

1 reference

2 September 2017

3

1 reference

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

2 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20023

A synergistic interaction of transcription factors AP2 and YB-1 regulates gelatinase A enhancer-dependent transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20023

Physical and functional interaction between two pluripotent proteins, the Y-box DNA/RNA-binding factor, YB-1, and the multivalent zinc finger factor, CTCF

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20023

Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20023

Chlorpyrifos oxon interacts with the mammalian multidrug resistance protein, P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20023

Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20023

Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20023

Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20023

Synthesis of active firefly luciferase by in vitro translation of RNA obtained from adult lanterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20023

Nuclear translocation of the Y-box binding protein by ultraviolet irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20023

Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20023

Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20023

Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20023

MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20023

Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20023

21 January 2018

Identifiers

DOI

10.1002/PROS.20023

1 reference

2 September 2017

1 reference